Cancer Treatment Reviews
Volume 27, Issue 1 , Pages 51-61 , February 2001

The use of anti-inflammatory drugs in cancer pain

References 

    REFERENCES
  1. Dahl JB, Kehlet H. Non-steroidal anti-inflammatory drugs: rationale for use in severe postoperative pain. Br J Anaesth. 1991;66:703–712
  2. Dahl JB, Brennum J, Arendt-Nielsen L, Jensen TS, Kehlet H. The effect of pre-versus post-injury infiltration with lidocaine on thermal and mechanical hyperalgesia after heat injury to the skin. Pain. 1993;53:43–51
  3. Malberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science. 1992;257:1276–1279
  4. McCormack K, Brune K. Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. Drugs. 1991;41:533–547
  5. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain. 1991;41:533–547
  6. Malberg AB, Yaksh TL. Pharmacology of the spinal action of ketorolac, morphine, ST-91, and L-PIA on the formalin test and an isobolographic analysis of NSAID interaction. Anesthesiology. 1993;79:270–281
  7. Fletcher D, Benoist J, Gautron M, Guilbaud G. Isobolographic analysis of interactions between intravenous morphine, proparacetamol, and diclofenac in carrageenin-injected rats. Anesthesiology. 1997;87:317–326
  8. De Conno F, Ripamonti C, Sbanotto A, Saita L, Zecca E, Ventafridda V. The pharmacological management of cancer pain. Part 1: the role of non opioid and adjuvant drugs. Ann Oncol. 1993;4:187–193
  9. Ventafridda V, Fochi C, De Conno F, Sganzerla E. Use of non-steroidal anti-inflammatory drugs in the treatment of pain in cancer. Br J Clin Pharmacol. 1980;10:343S–346S
  10. Bjorkman R, Ullman A, Hedner J. Morphine-sparing effect of diclofenac in cancer pain. Eur J Clin Pharmacol. 1993;44:1–5
  11. Mercadante S, Sapio M, Caligara M, Serretta R, Dardanoni G. Opioid-sparing effect of diclofenac in cancer pain. J Pain Symptom Manage. 1997;14:15–20
  12. Stillman MT, Schlesinger PA. Nonsteroidal anti-inflammatory drug nephrotoxicity. Arch Intern Med. 1990;44:643–653
  13. Mercadante S, Genovese G, Kargar JA. Home palliative care: results in 1991 versus 1988. J Pain Symptom Manage. 1992;7:414–418
  14. Ventafridda V, De Conno F, Panerai AE, Maresca V, Monza GC, Ripamonti C. Non-steroidal anti-inflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs. J Intern Med Res. 1990;18:21–29
  15. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59:850–856
  16. Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization guidelines for cancer pain relief: a 10 year prospective study. Pain. 1995;63:65–76
  17. Grond S, Zech D, Schug SA, Lynch J, Lehmann KA. The importance of non-opioid analgesics for cancer pain relief according to the guidelines of the World Health Organization. Int J Clin Pharm Res. 1991;6:253–260
  18. Mercadante S. Pain treatment and outcome in advanced cancer patients followed at home. Cancer. 1999;85:1849–1858
  19. Mercadante S. Similar pain in different countries. J Pain Symptom Manage. 1996;12:270–271
  20. Camu F, Lauwers MH, Vanlersberghe C. Side effects of NSAIDs and dosing recommendations for ketorolac. Acta Anaesthesiol Belg. 1996;47:143–149
  21. Eisemberg E, Berkey CS, Carr DB, Mosateller F, Chalmers C. Efficacy and safety of nonsteroidal antinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol. 1994;12:2756–2765
  22. Lyss AP, Portenoy RK. Strategies for limiting the side effects of cancer pain therapy. Semin Oncol. 1997;24:S16–28
  23. Ventafridda V, Toscani F, Tamburini M. Sodium naproxen versus sodium diclofenac in cancer pain control. Drug Res. 1990;40:1132–1134
  24. Ballantyne JC, Dershwitz M. The pharmacology of non-steroidal anti-inflammatory drugs for acute pain. Curr Opin Anesth. 1995;8:461–468
  25. Minotti V, Betti M, Ciccarese G, Fumi G, Tonato M, Del Favero A. A double-blind study comparing two single-dose regimens of ketorolac with diclofenac in pain due to cancer. Pharmacotherapy. 1998;18:504–508
  26. Yalcin S, Gullu IH, Tekuzman G, Savas C, Firat D. A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study. Am J Clin Oncol. 1998;21:185–188
  27. Pannuti F, Robustelli della Cuna G, Ventafridda V, Trocchi E, Camaggi CM. A double-blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TS/10 recordati Protocol Study Group. Tumori. 1999;85:96–100
  28. Staquet MJ. A double-blind study with placebo control of intramuscular ketorolac tromethamine in the treatment of cancer pain. J Clin Pharmacol. 1989;29:1031–1036
  29. Pace V. Use of nonsteroidal anti-inflammatory drugs in cancer. Palliat Med. 1995;9:273–286
  30. Toscani F, Piva L, Corli O. Ketorolac versus diclofenac sodium in cancer pain. Arzneimittelforschung. 1994;44:550–554
  31. Ventafridda V, Caraceni A, Sbanotto A. Cancer pain management. Pain Reviews. 1996;3:153–179
  32. Walker JS, Sheather-Reid RB, Carmody JJ, Vial JH, Day RO. Non steroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of “responders” and nonresponders. Arthritis Rheum. 1997;40:1944–1954
  33. Mercadante S, Maddaloni S, Roccella S, Salvaggio L. Predictive factors in advanced cancer pain treated only by analgesics. Pain. 1992;50:151–155
  34. Gillis JC, Brodgen RN. Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997;53:139–188
  35. Carlson RW, Borrison RA, Sher HB, Eisenberg PD, Mowry PA, Wolin EM. A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Pharmacotherapy. 1990;10:211–216
  36. Minotti V, Patoia L, Roila F. Double-blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain. 1989;36:177–183
  37. Estape J, Vinolas N, Gonzales B. Ketorolac, a new non-opioid analgesic: a double-blind trial versus pentazocine in cancer pain. J Int Med Res. 1990;18:298–304
  38. Minotti V, De Angelis V, Righetti E. Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain. Pain. 1998;74:133–137
  39. Rodriguez M, Barutell C, Rull M. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. Eur J Cancer. 1994;30A:584–587
  40. Stambaugh JE, Drew J. The combination of ibuprofen and oxycodone/acetaminophen in the management of chronic cancer pain. Clin Pharmacol Ther. 1988;44:665–669
  41. Dellemijn PLI, Verbiest HBC, Van Vliet JJ, Roos PJ, Vecht CJ. Medical therapy of malignant nerve pain: a randomised double-blind exploratory trial with naproxen versus slow release morphine. Eur J Cancer. 1994;30:1244–1250
  42. Picard P, Bazin JE, Conio N, Ruiz F, Schoeffer P. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. Pain. 1997;73:401–406
  43. Souter AJ, Fredman R, White PF. Controversies in the perioperative use of non-steroidal anti-inflammatory drugs. Anesth Analg. 1994;79:1178–1190
  44. Ferrer-Brechner T, Ganz P. Combination therapy with ibuprofen and methadone for chronic cancer pain. Am J Med. 1984;13:78–83
  45. De Conno F, Ripamonti C, Bianchi M, Ventafridda V, Panerai AE. Diclofenac does not modify morphine bioavailability in cancer patients. Pain. 1992;48:401–402
  46. Bianchi M, Clavenna A, Groff L, Zecca E, Ripamonti C. Diclofenac does not modify methadone bioavailability in cancer patients. J Pain Symptom Manage. 1999;17:227–228
  47. Bruera, E. Bone pain due to cancer. Paris, August 1993, 237, 244.
  48. Portenoy RK. Cancer pain management. Seminars in Oncology. 1993;20:19–35
  49. Ashburn MA, Lipman AG. Management of pain in the cancer patient. Anesth Analg. 1993;76:402–416
  50. Levy MH. Pharmacologic treatment of cancer pain. N Eng J Med. 1996;335:1124–1132
  51. Campa JA, Payne R. The management of intractable bone pain: a clinician’s perspective. Semin Nucl Med. 1992;222:3–10
  52. Gordon RL. Prolonged central intravenous ketorolac continuous infusion in a cancer patient with intractable bone pain. Ann Pharmacother. 1998;32:193–196
  53. Ashby MA, Fleming BG, Brooksbank M. Description of a mechanistic approach to pain management in advanced cancer. preliminary report. Pain. 1992;51:153–161
  54. Myers KG, Trotman IF. Use of ketorolac by continuous subcutaneous infusion for the control of cancer-related pain. Postgrad Med J. 1994;70:359–362
  55. Lundstam SOA, Leissner K, Wahlander LA, Kral JG. Prostaglandin-synthetase inhibition with diclofenac sodium in treatment of renal colic: comparison with use of a narcotic analgesic. Lancet. 1982;1:1096–1097
  56. Blackwell N, Bangham L, Hughes M, Melzack D, Trotman I. Subcutaneous ketorolac: a new development in pain control. Palliat Med. 1993;7:63–65
  57. Middleton RK, Lyle JA, Berger DL. Ketorolac continuous infusion: a case report and review of the literature. J Pain Symptom Manage. 1996;12:190–194
  58. Mercadante S, Casuccio A, Agnello A, Pumo S, Kargar J, Garofalo S. The analgesic effects of non-steroidal anti-inflammatory drugs (NSAIDs) in cancer pain due to somatic or visceral mechanism. J Pain Symptom Manage. 1997;17:351–356
  59. Vecht CJ. Nociceptive nerve pain and neuropathic pain. Pain. 1989;39:243–244
  60. Ripamonti C, Ticozzi C, Zecca E, Rodriguez CH, De Conno F. Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report. Tumori. 1996;82:413–415
  61. Tramer MR, William JE, Carroll D, Wiffen PJ, Moore RA, McQuay HJ. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand. 1998;42:71–79
  62. De Conno F, Zecca E, Martini C, Ripamonti C, Caraceni A, Saita L. Tolerability of ketorolac administered via continuous subcutaneous infusion for cancer pain: a preliminary report. J Pain Symptom Manage. 1994;9:119–121
  63. De Broe ME, Elseviers MM. Analgesic nephropathy. New Engl J Med. 1998;338:446–452
  64. Thatte L, Vaamonde CA. Dru-induced nephrotoxicity: the crucial role of risk factors. Postgrad Med. 1996;100:83–84
  65. Murray MD, Brater DC. Effects of NSAIDs on the kidney. Prog Drug Res. 1997;49:155–171
  66. Feldman HI, Kinman JL, Hennessyu S. Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med. 1997;126:193–199
  67. Hansen JM, Hallas J, Lauritsen JM, Bytzer P. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol. 1996;31:126–130
  68. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med. 1996;156:1530–1536
  69. Mercadante S, Barresi L, Casuccio A. Gastrointestinal hemorrhagic events in advanced cancer patients. J Pain Symptom Manage. 2000;19:160–162
  70. Garcia-Rodriguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risks: a collaborative meta-analysis. Semin Arthriris Rheum. 1997;26:16–20
  71. Wilcox CM, Clark WS. Association of nonsteroidal antiinflammatory drugs with outcome in upper and lower gastrointestinal bleeding. Dig Dis Sci. 1997;42:985–989
  72. Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Am J Med. 1994;94:274–281
  73. Hansen JM, Hallas J, Lauritsen JM, Bytzer P. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol. 1996;31:126–130
  74. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-unflammatory drugs and incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 1995;141:539–545
  75. Langman MJS, Well J, Wainwright P. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:1075–1078
  76. Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769–772
  77. Gillis JC, Brodgen RN. Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997;53:139–188
  78. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998;158:33–39
  79. Aitken HA, Burns JW, McArdle CS, Kenny GN. Effects of ketorolac trometamol on renal function. Br J Anaesth. 1992;68:481–485
  80. Laszlo A, Kelly JP, Kaufman DE. Clinical aspects of upper gastrointestinal bleeding associated with the use of nonsteroidal antiinflammatory drugs. Am J Gastroenterol. 1998;93:721–725
  81. Hallas J, Lauritsen J, Villadsen HD, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol. 1995;30:438–444
  82. McMahon AD, Evans JM, White G. A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation. J Clin Epidemiol. 1997;50:351–356
  83. Longstreth GF. Epidemiology of hospitalisation for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol. 1995;;90:206–210
  84. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med. 1998;104:23S–29S
  85. Bjorkman DJ, Kimmey MB. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease: pathophysiology, treatment and prevention. Dig Dis Sci. 1995;13:119–129
  86. Fenn GC, Morant SV. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol. 1997;36:817–819
  87. Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997;26 Suppl, 6:21–27
  88. Fry SW, Seeff LB. Hepatotoxicity of analgesics and anti-inflammatory agents. Gastroenterol Clin North. 1995;24:875–905
  89. Farrell GC. Drug-induced hepatic injury. J Gastroenterol Hepatol. 1997;12:S242–S250
  90. Stambaugh JE. Role of nonsteroidal anti-inflammatory drugs in the management of cancer pain. In:  Patt RB editors. Cancer Pain. Philadelphia: JB Lippincott Co; 1993;p. 105–117
  91. Agrawal NM, Aziz K. Prevention of gastrointestinal complications associated with nonsteroidal antiinflammatory drugs. J Rheumatol. 1998;51:17–20
  92. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med. 1996;;28:204–210
  93. Valentini M, Cannizzaro R, Poletti M. Nonsteroidal anti inflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastroitestinal damage. J Clin Oncol. 1995;13:2637–2642
  94. Silverstein FE, Graham DY, Senior JR. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomised, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241–249
  95. Champion GD, Feng PH, Azuma T. NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus. Drugs. 1997;53:6–19
  96. Yeomans ND, Tulassay Z, Jush’asz L. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:719–726
  97. Hawkey CJ, Karrasch JA, Szczepanski L. Omeprozole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:727–734
  98. Downie WW. Prostaglandins and NSAID in the kidney. J Rheumatol. 1991;18 Suppl, 28:19–21
  99. Shield MJ. Diclofenac/misoprostol: novel findings and their clinical potential. J Rheumatol. 1998;51:31–41
  100. Tannenbaum H, Davies P, Russell AS. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. CMAJ. 1996;155:77–88

PII: S0305-7372(00)90192-0

doi: 10.1053/ctrv.2000.0192

Cancer Treatment Reviews
Volume 27, Issue 1 , Pages 51-61 , February 2001

Article Tools